載入中
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
前收盤價
US$0.33
+US$0.007 · +2.17%
盤後
US$0.33
US$0.00 · 0.00%
10月7日 下午7:19 ET
盤中時間採用ET。市場資料可能有所延遲。
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
日內區間
目前US$0.33
52週區間
目前US$0.33
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
強力賣出
估值
8
估值過高
情緒
39
看跌
風險
81
極高風險
動能
30
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
日內區間
目前US$0.33
52週區間
目前US$0.33
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.2萬 USD | — | 197.8萬 USD | 328.6萬 USD | 229.1萬 USD |
| 銷貨成本 | 363.7萬 USD | — | — | — | — |
| 毛利 | −361.5萬 USD | — | 197.8萬 USD | 328.6萬 USD | 229.1萬 USD |
| 研究與開發 | 3758.6萬 USD | 3435.6萬 USD | 3215萬 USD | 2814.5萬 USD | 2195.7萬 USD |
| 銷售、一般及管理費用 | 2616.3萬 USD | 2351萬 USD | 3486.8萬 USD | 3763.3萬 USD | 2125萬 USD |
| 營業費用 | 6011.2萬 USD | 6103.9萬 USD | 9470.5萬 USD | 6537萬 USD | 4273.7萬 USD |
| 利息收入 | 92.7萬 USD | 94.8萬 USD | 286.4萬 USD | 170.1萬 USD | 1.1萬 USD |
| 折舊和攤銷 | 363.7萬 USD | 585.1萬 USD | 542.9萬 USD | 392萬 USD | 301萬 USD |
| 營業利益 | −6372.7萬 USD | −6103.9萬 USD | −9272.7萬 USD | −6208.4萬 USD | −4044.6萬 USD |
| 淨利 | −6143.8萬 USD | −5279萬 USD | −7105.8萬 USD | −5821萬 USD | −5531.9萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 1718.18%評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
